Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**VITIS CPC Protect** is a Dentaid oral antiseptic mouthwash formulated with **0.07% cetylpyridinium chloride** for daily reduction of dental plaque and oral biofilm. Cetylpyridinium chloride is a cationic quaternary-ammonium antiseptic that disrupts microbial cell membranes. The mouthwash has also been evaluated by Dentaid in a randomized pilot clinical study for prevention and reduction of symptoms associated with viral upper respiratory tract infections; this investigational use should not be interpreted as established efficacy for viral respiratory infections.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on VITIS CPC Protect.